—
It takes an average of 10 to 15 years and roughly $2.6 billion to bring a single new drug to market in the United States. By the time a treatment reaches patients, thousands of promising compounds have failed, billions of dollars have been spent, and families have waited far too long. Those delays don’t just cost money, they also cost lives.
Dr. Marek Polák wants to help fix that. A nationally regarded biochemist, he researches the smallest pieces of life, including proteins and nucleic acids. He aims to build faster, smarter tools for drug discovery. Dr. Polák’s work focuses on mass spectrometry, a technology that can detect and identify molecules with stunning precision. “Mass spectrometry is a powerful analytical tool that allows us to study molecules with extreme precision,” he says. “Higher mass resolution and accuracy reduce uncertainty in early-stage research and help eliminate ineffective candidates sooner.”
The impact is massive. Every minute shaved off research, every failed trial avoided, saves both time and billions of dollars. More importantly, it moves life-saving drugs from theory to pharmacy shelves faster than ever before.
Dr. Polák’s work zeroes in on the backbone of modern biotech and how we see what’s happening inside our cells. Current testing often relies on indirect markers like symptoms or basic blood chemistry. He’s helping replace that with direct molecular fingerprinting capable of spotting thousands of proteins from a drop of blood. “Many diagnostic errors occur because current tests rely on indirect markers rather than the molecules that actually drive disease,” he explains. “Mass spectrometry can detect and quantify thousands of proteins or metabolites from a single drop of blood.”
The National Academy of Medicine estimates that diagnostic errors contribute to as many as 80,000 deaths in the U.S. each year. Tools that catch disease earlier, or distinguish between two illnesses that look alike, could save countless lives and cut healthcare costs across the board.
The United States spends nearly $4.9 trillion on healthcare annually, with chronic disease and late-stage treatments accounting for most of it. Dr. Polák believes better technology could bring better health to all Americans. “Today’s technology could potentially be built on early detection, which will prevent expensive treatments at a late stage of disease,” he says. Faster, more accurate screening means fewer failed trials, fewer misdiagnoses, and less waste. This could be savings that ripple through insurance systems, hospitals, and households alike.
What’s striking about his work is how widely it applies. The same molecular-level precision that helps doctors diagnose cancer can help environmental scientists detect pollutants, or food-safety labs identify contamination before it hits the supply chain. High-resolution instruments even guide research in energy, materials science, and space exploration.
“One major misconception is that innovation happens in sudden ‘Eureka!’ moments,” Dr. Polák says. “In reality, it’s an iterative process built on years of foundational work, trial and error, and of course collaboration.” His journey from Charles University in Prague, where he earned his Ph.D. in Biochemistry, to one of America’s most advanced research facilities is proof of persistence that creates real results.
The challenge, he adds, isn’t just discovery, it’s translation. “The biggest challenge is bridging the scientific experiment into the possible real-life result,” he explains. That gap between lab bench and hospital bed is where time, regulation, and cost often stall progress. His mission is to help bridge it.
Dr. Polák envisions a future where mass spectrometry underpins personalized medicine. Imagine a routine blood test that maps your body’s molecular profile and tells doctors exactly what you need. This could be a new therapy, a diet change, or early intervention for a hidden risk. “I envision a future where advanced molecular analysis enables truly personalized and preventive healthcare,” he says. “Imagine a routine blood test that maps your body’s molecular state and guides nutrition, lifestyle, or therapy choices tailored specifically to you.”
If he succeeds, America’s healthcare system could finally shift from reactive to preventive, saving billions while improving quality of life for millions. It’s not as flashy as inventing a miracle cure, but the ripple effect could be even more transformative. Shorter timelines. Lower costs. Fewer errors. Better outcomes.
And it all starts by looking closer. Because the atoms that shape our health also shape our economy, our treatments, and the future of American medicine. When we can read them with precision, we give the country a chance to build a system that actually works for everyone.
—
This content is brought to you by Melissa Moraes.
Photo provided by the author.
